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AbstrAct
Objective Mortality amongst patients hospitalised for 
heart failure (HHF) in Western and Asian countries may 
differ, but this has not been investigated using individual 
patient-level data (IPLD). We sought to remedy this through 
rigorous statistical analysis of HHF registries and variable 
selection from a systematic literature review.
Methods and results IPLD from registries of HHF in 
Japan (n=3781) and the UK (n=894) were obtained. 
A systematic literature review identified 23 models for 
predicting outcome of HHF. Five variables appearing in 
10 or more reports were strongly related to prognosis 
(systolic blood pressure, serum sodium concentration, 
age, blood urea nitrogen and creatinine). To compare 
mortality in the UK and Japan, variables were imputed in 
a propensity model using inverse probability of treatment 
weighting (IPTW) and IPTW with logistic regression (doubly 
robust IPTW). Overall, patients in the UK were sicker and 
in-patient and post-discharge mortalities were greater, 
suggesting that the threshold for hospital admission was 
higher. Covariate-adjusted in-hospital mortality was similar 
in the UK and Japan (IPTW OR: 1.14, 95% CI 0.70 to 1.86), 
but 180-day postdischarge mortality was substantially 
higher in the UK (doubly robust IPTW OR: 2.33, 95% CI 
1.58 to 3.43).
Conclusions Despite robust methods to adjust for 
differences in patient characteristics and disease severity, 
HHF patients in the UK have roughly twice the mortality 
at 180 days compared with those in Japan. Similar 
analyses should be done using other data sets and in other 
countries to determine the consistency of these findings 
and identify factors that might inform healthcare policy 
and improve outcomes.
IntrOduCtIOn
Annually, heart failure (HF) accounts 
for >80 000 admissions in the UK,1 >200 000 
in Japan2 3 and >1 million in the USA. Among 
patients hospitalised for heart failure (HHF), 
in-hospital mortality is reported to vary from 
2.0% to 12.0%1 3–10 and mortality at 1-year 
postdischarge from 13.3% to 30.5%.1 6 8 11 
Differences in mortality estimates for HHF 
might be due to variations in patient char-
acteristics, severity of HF, comorbidities or 
medical care. Substantial international differ-
ences in health service provision may also 
exist, including criteria for admission, length 
of stay, care in the community after discharge 
and treatment. There will also be cultural 
differences in both the art of medicine and 
patient attitudes to medical advice, especially 
between Western and Asian countries. To 
date, outcomes for HHF in different health-
care systems have been investigated only using 
aggregate rather than individual patient-level 
data (IPLD). Comparing the characteristics 
and outcomes of HHF managed in different 
cultures might identify differences in practice 
that could improve care.
Key questions
What is already known about this subject?
 ► The outcome of patients hospitalised for  heart 
failure (HHF) is reported to differ markedly among 
different countries/healthcare systems, despite sim-
ilarity in international guidelines on management.
 ► However, this has not been investigated using in-
dividual patient-level data with rigorous statistical 
analyses.
What does this study add?
 ► We directly compared patient characteristics and 
outcomes in the UK and Japan.
 ► HHF patients in the UK have roughly twice the mor-
tality at 180 days compared with those in Japan 
even after adjustment by inverse probability of 
treatment weighting (IPTW) and IPTW with logistic 
regression (doubly  robust IPTW) using covariates 
strongly associated with mortality identified by a 
systematic literature review of mortality prediction 
models.
How might this impact on clinical practice?
 ► In HHF patients, explaining the  differences in out-
come among countries, cultures and health services 
independent from disease severity might provide 
insights that could improve care and outcome and 
inform healthcare policy decisions.
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Accordingly, we investigated in-hospital and post-dis-
charge mortality using IPLD from registries of HHF in the 
UK and Japan, adjusting for differences in key prognostic 
variables identified from a systematic review of published 
mortality prediction models (MPMs) and using inverse 
probability of treatment weighting (IPTW) techniques.
MetHOds
Overall study design
Our main objective was to compare the mortality of 
HHF patients in the UK and Japan after adjusting for 
differences in baseline covariates. This involved three 
steps: (1) first, a systematic review of published MPMs 
for HHF, identifying the variables predicting mortality 
and estimating their respective predictive weights; (2) 
subsequently, the predictors identified by the review were 
imputed in a propensity model using IPTW to identify 
patients with similar attributes in the UK and Japan; 
and (3) finally, outcomes of interest between the weighted 
groups, including in-hospital, 30-day, 90-day and 180-day 
post-discharge mortality, were evaluated.
systematic review
We searched the Medline/PubMed and Embase data-
bases to identify relevant MPMs. We employed search 
filters that have been validated and shown to have high 
sensitivity for identification of clinical prediction models 
in Medline12 (online supplementary appendix) toSupple-
mentary file 1 identify 4487 MPMs for HHF. Those with 
models only for composite outcomes (ie, HF hospitali-
sation and mortality), those published only as abstracts 
and duplicate reports were excluded. We also excluded 
studies when model performance was not quantified 
using c-statistics or receiver operating characteristic 
curves. This identified 23 unique MPMs from which 
information on individual predictor variables could be 
extracted. For the meta-analyses, studies lacking OR or 
HR for predictor variables were excluded; 17 studies were 
finally included in the meta-analysis (figure 1). All studies 
were reviewed by two independent cardiologists (TN and 
VS) to ascertain eligibility (see online supplementary 
table for details on data extraction and reduction, and 
statistical analysis).
study cohorts
Pooled data from two UK and two Japanese registries 
of HHF were used. In all registries, HHF was defined by 
hospitalisation with a diagnosis of HF according to the 
Framingham criteria.
UK HHF cohort
1. The Hull and East Yorkshire Hospitals NHS Trust, 
King’s College Hospital NHS Foundation Trust 
(London) and Whittington Hospital NHS Trust 
(London) are three large tertiary care hospitals 
that each provides emergency care to approximate-
ly 500 000 people. All three Trusts participate in the 
England and Wales National Heart Failure Audit.1 
From 2012 to 2013, 697 HHF patients (307 from 
Hull; 390 from London) were enrolled. Because 
it is a National Health Service (NHS) registry, nei-
ther specific ethical review nor patient consent is 
required.
2. The Hull LifeLab is a large, epidemiologically repre-
sentative, information-rich data set of contemporary 
diagnosis, treatment and natural history of patients 
with HF. Its main focus is on out-patient referrals13; 
only patients hospitalised for HF at the time of enrol-
ment between 2010 and 2011 (n=197) were included 
in this analysis. The registry has ethical approval and 
patients gave written informed consent.
Japanese HHF cohort
1. The WET-HF (WEst Tokyo Heart Failure) registry is an 
ongoing, prospective observational registry of HHF in 
five large academic medical centres in metropolitan 
Tokyo that enrolled 3030 patients between 2005 and 
2016.14
2. The NaDEF (National cerebral and cardiovascular 
center for acute DEcompensated heart Failure) regis-
try enrolled 751 patients between 2013 and 2015 from 
a large centre for cardiovascular medicine located in 
mid-west Japan.15
The study protocols were registered at the Japa-
nese University hospital Medical Information Network 
(UMIN) Clinical Trial Registration (UMIN000001171 
and UMIN000017024, respectively).
statistical analysis
The weights of variables predicting mortality were 
meta-analysed, using fixed-effect and random-effect 
models. The z-scores (OR/SE and HR/SE) of the OR (for 
case–control studies) and the HR (for cohort studies) of 
predictor variables were estimated.16 Continuous varia-
bles were presented as mean±SD. Baseline variables that 
were significantly different between the two groups were 
identified using standardised differences. Among these 
variables, those that were used in more than one MPM 
(n≥2) and available in both countries were imputed in 
an IPTW model to develop balanced groups.17 Balance 
between the British and Japanese weighted cohorts was 
evaluated using the standardised differences approach 
and kernel density plots. For propensity analyses, IPTW 
was preferred over matching in order to preserve the 
sample size.18
We performed univariable/multivariable logistic 
regression analyses, IPTW and IPTW with logistic 
regression (doubly robust IPTW) to compare odds for 
mortality (in-hospital, 30-day postdischarge, 90-day post-
discharge and 180-day postdischarge) in the UK and 
Japanese cohorts. Additional analysis was performed for 
postdischarge mortality after controlling for medicines at 
discharge. All analyses were performed with Stata MP64 
V.15.
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results
systematic review of MPMs
We identified 28 different MPMs from 23 papers 
published between 2003 and 2017 (online supplemen-
tary table). The five variables with the top z-scores were 
systolic blood pressure (BP), serum sodium concentra-
tion, age, blood urea nitrogen (BUN) and serum creati-
nine; 26 predictor variables appeared in more than one 
MPM (table 1).
Cohort baseline characteristics
The baseline characteristics of patients in the UK (n=894) 
and Japan (n=3781) are shown in table 2. The mean age 
was similar in UK and Japan, but British patients had 
more severe HF as evidenced by higher New York Heart 
Association (NYHA) class, lower systolic BP, lower serum 
sodium concentrations, higher BUN and serum creati-
nine concentrations. A higher proportion of Japanese 
patients had a left ventricular ejection fraction >45%. 
The prevalence of ischaemic heart disease and chronic 
pulmonary obstructive disease (COPD)/asthma was 
higher among British patients compared with their Japa-
nese counterparts.
Inverse probability of treatment weighting
After application of IPTW with variables which were 
used in two or more MPMs and available in both coun-
tries (systolic BP, hyponatraemia, age, serum creatinine, 
COPD/asthma, heart rate, NYHA class, ischaemic heart 
disease, stroke, left ventricular ejection fraction, atrial 
fibrillation, diabetes mellitus and sex), there was good 
balance between British and Japanese patients’ char-
acteristics. Standardised differences were <0.1 for most 
variables other than haemoglobin and medications at 
discharge. After additional weighting for oral medica-
tions at discharge (ACE inhibitor/angiotensin II receptor 
Figure 1 Flow diagram of the meta-analyses of published mortality prediction models in HHF patients. AUC, area under the 
curve; HHF, hospitalised due to heart failure. 
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blocker, beta blocker, mineralocorticoid receptor antago-
nist, diuretics and digitalis), balance (standardised differ-
ence <0.1) was achieved for all key variables (table 2).
Mortality before and after IPtW in the uK compared with 
Japan
Crude analyses showed that mortality was substantially 
higher in the UK compared with Japan at all time-points 
(table 3). Unadjusted mortality during hospitalisation 
was 3.6% in the UK vs 2.2% in Japan, and was, respec-
tively, 3.5% vs 2.7% at 30 days, 9.0% vs 4.4% at 90 days, and 
14.7% vs 6.3% at 180 days. Multivariable logistic regres-
sion analyses in the unweighted population showed that 
in-hospital mortality was similar in the UK and Japan, but 
British patients had a substantially higher mortality by 180 
days (table 3). Weighted and doubly robust weighted anal-
yses also showed higher mortality in the UK at 180 days. 
Because of the low number of events, we did not have the 
statistical power to perform doubly robust weighted anal-
yses for in-hospital, 30-day (with and without accounting 
for medications at discharge) and 90-day mortality (after 
accounting for medications at discharge) (table 3).
dIsCussIOn
This analysis suggests that HHF patients in the UK have 
more advanced disease than their Japanese counterparts 
and a much worse prognosis. After adjusting for differ-
ences in patient characteristics using IPTW, in-hospital 
mortality was similar in the UK and Japan, suggesting that 
the quality of in-patient care might be similar. However, 
substantial differences in post-discharge mortality 
persisted even after adjusting for the prognostic varia-
bles that were identified by a systematic literature review 
and available in both countries. As far as we know, this is 
the first analysis comparing HHF in Western and Asian 
Table 1 Frequency of variables used in the models to predict mortality after hospitalisation for heart failure and their 
respective weights
Variables n
OR HR
z-Score Mean 95% CI z-Score Mean 95% CI
Systolic blood pressure 21 42.62 1.17 1.11 to 1.23 51.40 1.18 1.13 to 1.22
Serum sodium 21 43.27 1.15 1.09 to 1.20 17.40 1.20 1.06 to 1.33
Age 21 21.09 1.41 1.28 to 1.54 14.08 1.39 1.19 to 1.58
Blood urea nitrogen 16 27.44 1.57 1.46 to 1.68 39.86 1.29 1.22 to 1.35
Creatinine 14 12.73 1.33 1.12 to 1.53 9.29 1.43 1.13 to 1.73
COPD/asthma 8 10.00 1.53 1.23 to 1.82 12.86 1.44 1.22 to 1.66
Heart rate 7 45.24 1.18 1.13 to 1.23 – – – 
Albumin 6 34.73 1.57 1.48 to 1.66 11.26 1.42 1.17 to 1.66
Haemoglobin 6 15.11 1.30 1.13 to 1.47 – – – 
Cancer 6 7.75 2.45 1.83 to 3.07 – – – 
NYHA class 6 4.57 2.26 1.29 to 3.03 – – – 
Ischaemic heart disease 4 – – – 23.95 1.21 1.11 to 1.30
Dementia 4 20.05 1.85 1.67 to 2.03 – – – 
Stroke 4 10.31 1.38 1.12 to 1.64 – – – 
Oxygen saturation 4 2.02 2.05 0.07 to 4.03 – – – 
Respiratory rate 3 34.59 1.18 1.11 to 1.24 – – – 
Sex 3 30.59 1.29 1.20 to 1.37 – – – 
LVEF 3 9.62 1.15 0.91 to 1.38 – – – 
(N-terminal pro) BNP 3 7.05 1.85 1.33 to 2.36 – – – 
Transfer by EMS 3 5.74 3.81 2.51 to 5.11 – – – 
Liver cirrhosis 3 2.20 4.01 0.44 to 7.58 – – – 
Prior heart failure hospitalisation 3 – – – – – – 
Potassium 3 – – – – – – 
Troponin 3 – – – – – – 
Atrial fibrillation 3 – – – – – – 
Diabetes mellitus 2 – – – – – – 
BNP, brain natriuretic peptide; COPD, chronic pulmonary obstructive disease; EMS, emergency medical service; LVEF, left ventricular ejection 
fraction; NYHA, New York Heart Association.
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countries using IPLD data with doubly robust IPTW. 
The fact that different methods of adjustment provided 
similar results suggests that our study has considerable 
internal validity.
Globally, HHF patients are common, and the numbers 
are expected to rise as the proportion of older people in 
the population increases and survival with conditions such 
as hypertension, ischaemic heart disease and HF itself 
improves.2 19–21 Internationally, guidelines on the manage-
ment of HF are rather similar but less is known about 
the differences among patients from different cultures 
and countries to whom the guidelines are applied. For 
example, HHF patients in Japan are reported to have a 
longer length of hospital stay (Japan: 15–21 days; Europe: 
7–9 days; USA: 4 days) and lower in-hospital mortality 
than patients in Europe and the USA (Japan: 2.0%–
5.6%; Europe: 5.5%–6.7%; USA: 3.8%–8.9%).4–7 10 22–24 
However, these are crude estimates unadjusted for differ-
ences in disease severity. We identified 26 prognostic vari-
ables for HHF in a systematic review and used these to 
adjust for variations in patient characteristics that might 
have accounted for the differences in mortality. To our 
knowledge, this is the first systematic review of prognostic 
variables for HHF; previous systematic reviews focused on 
chronic HF.16 Despite risk adjustment, 180-day postdis-
charge mortality remained substantially higher in the UK 
than in Japan.
Differences in post-discharge mortality could reflect 
many factors, including genetics, aetiology of disease, 
post-discharge care, lifestyle, diet, environment or other 
unmeasured confounders. For instance, in Japan it is 
customary for patients with HF to be seen in the outpa-
tient clinic within 4 weeks after discharge, even if the HF 
is not severe, whereas in the UK patients are more likely 
to be managed in the community by HF specialist nurses 
and primary care physicians. The Japanese diet will 
include more rice and less wheat, more salt, more fish, 
and less red meat.25 The weather is warmer in Tokyo 
than in England. Japanese patients may be more likely 
to follow medical advice and adhere to their prescribed 
medication. On the other hand, Japanese doctors gener-
ally prescribe much lower doses of medicines than their 
British colleagues.26–28 While our analysis estimates the 
differences in outcomes after adjusting for identified 
predictor variables, it was not designed to identify the 
reason for residual disparities.
limitations
While both the UK and Japan registries had detailed 
IPLD, certain important variables that were identified 
from a systematic literature review, such as respiratory 
rate, serum albumin, troponin and plasma brain natriu-
retic peptide levels, and medication compliance, were 
not consistently available. This study is geographically 
limited to patients hospitalised in Britain and Japan, and 
our results may not generalise to other Western or Asian 
countries. Finally, the study was not designed to identify 
the reason for residual disparities. However, we believe T
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Heart failure and cardiomyopathies
that these limitations are outweighed by methodolog-
ical strengths, including prospective patient enrolment 
from multiple centres, a systematic review to identify 
predictor variables and their estimated weights, and the 
use of multiple adjustment methods including conven-
tional covariate adjustment, IPTW and doubly robust 
IPTW, all of which yielded similar results.
COnClusIOn
HHF patients in the UK have a substantially worse prog-
nosis compared with those hospitalised in Japan. Differ-
ences persist after accounting for the greater severity 
of patients admitted with HF in the UK. Explaining 
the differences in outcome among countries, cultures and 
health services might provide insights that could improve 
care and outcome and inform healthcare policy decisions.
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